Kinpeygo

Budesonide, the active ingredient in Kinpeygo, is a corticosteroid presented as an oral formulation for oral use. It is indicated for the treatment of inflammatory bowel disease, specifically Crohn's disease and ulcerative colitis, helping to reduce intestinal inflammation and maintain remission in adult patients.

GNH USA supplies Kinpeygo as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under EU quality standards. The company ensures consistent batch release and regulatory compliance for global distribution.

Budesonide is a corticosteroid that reduces gastrointestinal inflammation in inflammatory bowel disease.

Crohn's disease: reduces intestinal inflammation and promotes remission. Ulcerative colitis: helps achieve clinical remission and mucosal healing. Inflammatory bowel disease: provides overall disease activity control.

Adverse reactions to Kinpeygo may vary in frequency and severity.

Common Side Effects: - Nausea - Headache - Abdominal pain - Upper respiratory tract infection

Serious or Rare Side Effects: - Adrenal suppression - Severe infections - Perforated gastrointestinal ulcer

When using Kinpeygo, consider the following precautions.

Assess adrenal function: evaluate baseline cortisol levels before long‑term therapy. Monitor for infections: watch for signs of bacterial, viral or fungal infections during treatment. Evaluate bone health: consider calcium and vitamin D supplementation for patients at risk of osteoporosis. Use with caution in hepatic impairment: dose adjustment may be required in moderate liver disease. Store at ambient temperature: keep in the original container, protect from moisture and light.

Kinpeygo may interact with other medicines; review the following.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure. - Systemic immunosuppressants (e.g., azathioprine) when combined may heighten infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin): may reduce budesonide effectiveness. - Anticoagulants (e.g., warfarin): may require INR monitoring. - NSAIDs: may increase risk of gastrointestinal ulceration.